Clinical
Dedicated to protecting the health of expectant mothers, their babies and families, PerkinElmer provides a comprehensive portfolio of screening and diagnostic solutions that enable the early clinical insights that have become essential for a pro-active approach to healthcare.
As the leader in life-saving screening tests for newborns, our instruments and technologies save approximately 70 babies every day by detecting over 50 congenital disorders early enough in a pregnancy for physicians to administer necessary treatments for better outcomes. Our newest prenatal screening solutions allow OBGYNs to offer high-precision and cost-effective NIPT to more expectant women and to identify - within the first trimester - those who are at a greater risk for pre-eclampsia.
Collaborating with governments and health organizations around the world, our scientists and engineers are focused on; pioneering work in prenatal risk assessment and neonatal screening; delivering next-generation instrumentation and diagnostic capabilities; and providing cord-blood stem-cell banking services.
Newborn Screening Around The World
Pre-eclampsia
Noninvasive Prenatal Testing (NIPT)
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada.
Please check with your local representative for availability.
Areas of Interest
Maternal & Fetal Health
When it comes to risk assessment and diagnosis of prenatal aneuploidy and pre-eclampsia, early detection is essential.
Newborn Screening
PerkinElmer is the global market leader in neonatal screening, currently serving customers in more than 100 countries.
Cord Blood & Tissue Banking
Your Family is Your Everything. Now is the time to start planning for your family's future health.
Genomics
PerkinElmer Genomics provides one of the world’s most comprehensive programs for detecting clinically significant genomic changes.
Stories
Collaborating to better detect Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy affects one in every 3,500 boys born each year. Dr. Stuart Moat and Dr. Ian Weeks developed a new fluorescence-based in vitro diagnostic kit...
ASPRE study signals a new era in pre-eclampsia management
The largest prospective, randomized placebo controlled trial recently took place to study the prophylactic use of aspirin in women at increased risk of pre-eclampsia.
New advances in first trimester prenatal screening
North York General Hospital researchers have developed an Enhanced First Trimester Screen that is faster, less costly, but just as accurate as the standard Integrated Prenatal Screening protocol in detecting the risk for Down syndrome and Trisomy 18.
Innovation
Innovation in Newborn Screening
Meet Anna Potier, scientist in our Waltham Diagnostics R&D group at PerkinElmer. Anna has used her knowledge of chemistry, mass spectrometry, multi-factor optimization and problem-solving to become an indispensable member of the Lysosomal Storage Disorder, or “LSD,” assay development team. She has been the lead author of several posters and a coauthor on two peer-reviewed publications, with more in the pipeline. In addition, she is the sole inventor on a patent application that is powerfully enabling of multiplex LSD enzyme activity assays.
Innovation in Pre-eclampsia Research - ASPRE Trial Results
Kypros Nicolaides, Professor of Fetal Medicine, King’s College, London has carried out extensive research in fetal diagnosis and therapy, leading to the publication of more than 1,200 peer-reviewed papers in scientific journals. He has provided training in Fetal Medicine to more than 500 doctors from 50 countries and has encouraged many more young doctors to undertake research in the field. In 1995, he founded the Fetal Medicine Foundation, which has donated more than £15 million to promote research and training in Fetal Medicine throughout the World.